Patent details
LUC00241
Product Name:
Satralizumab
Basic Information
- Publication number:
- LUC00241
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
-
EP098161847
- Legal Status:
- Inactive
- Application number:
- LUC00241
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
- Marketing Authorization Number:
- EU/1/21/1559
- Marketing Authorization Type:
-
- Marketing Authorization Date:
- 29/06/2021
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
- Luxembourg (LU)
Dates
- Filing date:
- 16/11/2021
- First Marketing Authorization date:
- 29/06/2021
- Grant date:
- 03/02/2025
- Activation date:
- Publication date:
- 16/11/2021
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 25/09/2034
- SPC Extension Expiration:
- 25/09/2034
- Rejection date:
- Withdrawal date:
Owner
- From:
- 16/11/2021
-
-
- Name:
- Chugai Seiyaku Kabushiki Kaisha
- Address:
- 5-1, Ukima 5-chome, Kita-ku Tokyo 115-8543, Japan (JP)
Agent
- Name:
- OFFICE FREYLINGER S.A.
- From:
- 16/11/2021
- Address:
- Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
- To:
Publication
Bulletin
1
- Bulletin Heading:
- SPC1
- Bulletin edition number:
- 2021/13
- Publication date:
- 02/12/2021
- Description:
- Section C : Published requests for Supplementary Protection Certificates – I1 publication
2
- Bulletin Heading:
- SPC2
- Bulletin edition number:
- 2025/04
- Publication date:
- 04/03/2025
- Description:
- Section D : Granted supplementary protection certificates – I2 publication
Annual Fees
- Annual Fee Due Date:
- 01/10/2029
- Annual Fee Number:
- 21
- Annual Fee Amount:
- 410 Euro
- Expected Payer:
-
- Last Annual Fee Payment Date:
-
- Last Annual Fee Paid Number:
-
- Payer:
-